JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on November 4, 2005
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
280/44/36626    most recent
M507236200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muenster, U.
Right arrow Articles by Fischer, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muenster, U.
Right arrow Articles by Fischer, W. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print August 29, 2005
J. Biol. Chem, 10.1074/jbc.M507236200
Submitted on July 5, 2005
Accepted on August 29, 2005

An activin-A/C chimera exhibits activin and myostatin antagonistic properties

Uwe Muenster, Craig A. Harrison, Cynthia Donaldson, Wylie Vale, and Wolfgang H. Fischer

The Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, CA 92037

Corresponding Author: fischer{at}salk.edu

Activins are involved in many physiological and pathological processes and, like other members of the TGF-beta superfamily, signal via type II and type I receptor serine kinases. Ligand residues involved in type II receptor binding are located in the two anti-parallel beta strands of the TGF-beta proteins, also known as the fingers. Activin-A mutants able to bind ActRII but unable to bind the activin type I receptor ALK4 define ligand residues involved in ALK4 binding and could potentially act as antagonists. Therefore, a series of FLAG tagged activin-A/C chimeras were constructed, in each of which 8 residues in the wrist loop and helix region (A/C 46-53, 54-61, 62-69, 70-78) were replaced. Additionally, a chimera was generated in which the entire wrist region (A/C 46-78) was changed from activin-A to activin-C. The chimeras were assessed for ActRII binding, activin bioactivity as well as antagonistic properties. All five chimeras retained high affinity for mouse ActRII. Of these, only A/C 46-78 was devoid of significant activin bioactivity in an A3 Lux reporter assay in 293T cells at concentrations up to 40nM. A/C 46-53, 54-61, 62-69 and A/C 70-78 showed activity comparable to wild-type activin-A. When tested for the ability to antagonize ligands that signal via activin type II receptors, such as activin-A and myostatin, only the A/C 46-78 chimera showed antagonism (IC50: 1-10 nM). Additionally, A/C 46-78 decreased FSH release from the Lbeta T2 cell line and rat anterior pituitary cells in primary culture in a concentration-dependent manner. These data indicate that activin residues in the wrist are involved in ALK4 mediated signaling. The activin antagonist A/C 46-78 may be useful for the study and modulation of activin-dependent processes.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. V. Korupolu, U. Muenster, J. D. Read, W. Vale, and W. H. Fischer
Activin A/Bone Morphogenetic Protein (BMP) Chimeras Exhibit BMP-like Activity and Antagonize Activin and Myostatin
J. Biol. Chem., February 15, 2008; 283(7): 3782 - 3790.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
S J. Lin, T. F Lerch, R. W Cook, T. S Jardetzky, and T. K Woodruff
The structural basis of TGF-{beta}, bone morphogenetic protein, and activin ligand binding.
Reproduction, August 1, 2006; 132(2): 179 - 190.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. A. Harrison, K. L. Chan, and D. M. Robertson
Activin-A Binds Follistatin and Type II Receptors through Overlapping Binding Sites: Generation of Mutants with Isolated Binding Activities
Endocrinology, June 1, 2006; 147(6): 2744 - 2753.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.